Mechanism of Action: Semaglutide: It stimulates the GLP-1 receptors, leading to increased insulin secretion and reduced glucagon release, thereby lowering blood sugar levels
Signs that insulin may be needed include persistently elevated blood sugar despite maximum GLP-1 doses, declining endogenous insulin production, and treatment plateaus that suggest the incretin-based approach has reached its limits
Methods A total of 114 participants across 10 countries participated in a two-round Delphi panel (9.7% drop-off rate between rounds)
Seek urgent medical advice
Heres what makes their semaglutide play a potential game-changer Scale over exclusivity Co-marketing deals with leading pharma players underway Multi-brand strategy = faster market penetration + deeper reach First-mover advantage in a post-patent gold rush Early entry into Indias GLP-1 opportunity Aggressive plans to expand across 90+ global markets Device-driven differentiation Pre-filled, disposable pen for easy self-administration Competing not just on molecule but on patient experience Higher-dose roadmap = lifecycle strategy Planned rollout of stronger doses Focus on long-term patient retention & therapy value Beyond pharma: Building a care ecosystem 65 Metabolic Centres of Excellence in the pipeline Driving awareness, adherence, and real-world outcomes Drug + Nutrition = Sticky strategy Targeted nutrition solutions alongside GLP-1 therapy Addressing side effects like muscle loss & appetite changes Premium generic positioning Not the cheapest in the market Competing on quality, convenience & integrated care The real battle is evolving Its no longer just about price
